Sigilon Therapeutics Inc., a Cambridge, Mass.-based startup working to encapsulate therapeutic cells for chronic disease inside microspheres invisible to the immune system's normal fibrotic response to foreign implants, has landed a $473 million deal with Eli Lilly & Co. to develop a potential treatment of type 1 diabetes (T1D).